NCT01468376终止1 期
An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations
研究概览
简要总结
The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Generally healthy adults between 21-65 years of age
- •Body Mass Index (BMI) between 25 and ≤40
- •OGTT (75g glucola) peak value between ≥140mg/dl and ≤199 mg/dl at screening visit
- •Willingness to adhere to the requirements of the protocol, including availability for follow-up visits and donation of blood samples
- •Willingness and ability to sign written informed consent
- •Women of child bearing capacity who agree to use an acceptable form of birth control during the trial [i.e., oral contraception, reliable use of a double-barrier method (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD or tubal ligation]
排除标准
- •Active diabetes mellitus [fasting blood glucose of ≥7.0 mmol/L (≥126 mg/dL) or ≥11.1 mmol/L (≥200 mg/dL) after OGTT]
- •Current coronary artery/ cardiovascular disease or history of a cardiovascular event (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary artery bypass grafting, angina pectoris) or have undergone a cardiovascular intervention within the past three months
- •Seizure disorder
- •Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men and less than 12 g/dL in women)
- •Active infection, including HIV, hepatitis, etc
- •Participants on Estrogen replacement must be on a stable dose for at least 3 months
- •Serious illness requiring ongoing medical care or medication
- •Gastrointestinal disorders or prior gastrointestinal surgeries (including gastric bypass or lap-band) that might cause complications or influence motility or satiety (e.g.,diverticulitis, inflammatory bowel disease, irritable bowel syndrome, intestinal narrowing or obstruction, difficulty swallowing)
- •Any congenital spinal cord deformities or traumatic spinal cord injuries
- •Uncorrected hypothyroidism
- •Other significant metabolic endocrine disease
- •Active liver disease or liver function impairment as evidenced by a history of liver disease or liver enzyme elevations >three times the upper limit of normal
- •Current cancer
- •Significant kidney disease (calculated by eGFR <60 mL/min)
- •History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological,or psychiatric disorders which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject
- •Use of anticoagulants such as warfarin
- •Use of medications that might affect weight or food absorption (e.g., diuretics,glucocorticoids, anorexigenic agents, Orlistat, laxatives)
- •Treatment within the previous 6 months with any medication that is known to affect glucose levels (such as insulin with or without an amylin analogue, sulfonylureas,meglitinides, biguanide metformin, thiazolidinediones, alpha-glucosidase inhibitors,oral dipeptidyl-peptidase-4 inhibitor, Sitagliptin, Incretin mimetic)
- •Regular use of natural health products or dietary supplements known to affect glucose levels (such as chromium, zinc, fenugreek, cinnamon). If the participant agrees to stop taking these products 14 days prior to study entry and for the duration of the study, they can participate in the study
- •o Any other natural health products or dietary supplements, with the exception of vitamins and minerals with dose of < 600 mg/day of vitamin E and containing no vitamin K. Natural health products or dietary supplements include products such as, but not limited to, Echinacea, Ginseng, St. John's Wort, Gingko, Glucosamine, Fish Oil supplements, Evening Primrose Oil, Green Tea or other herbal products consumed in the form of pills, extracts, capsules, or tablets. If the participant agrees to stop taking these products 14 days prior to study entry and for the duration of the study, they can participate in the study
- •Vegan or Vegetarian
- •Pregnant or lactating women, or intending to become pregnant
- •Known allergy to any ingredient in the study product
- •Any significant auto-immune disease
结局指标
主要结局
Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations
时间窗: 14 days
次要结局
- Safety and tolerability of GLU-xx formulations(14 Days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of Gemcabene in Adults With FPLDFamilial Partial LipodystrophyNASH - Nonalcoholic SteatohepatitisFatty LiverHypertriglyceridemiaNCT03508687Elif Oral5
已完成
2 期
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT02426372Qu Biologics Inc.11
已完成
1 期
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast CancerLocally Recurrent and Metastatic Breast CancerNCT00322400Amgen46
已完成
1 期
Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT00712114Harbor Therapeutics14
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsLung CancerLung CancerBreast CancerNCT06618287Bristol-Myers Squibb416